Business Wire

1. AutekBio, Suma Ventures And Beijing E-Town To Invest In The Largest CMO Project In Asia
   3/10/2010
   AutekBio, Inc., SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, a venture capital group from Beijing Municipal Government announced a joint investment of more than US$100m to develop a new contract manufacturing organization (CMO) for biopharmaceutical industry in China.
2. Glycos Biotechnologies Announces Successful Production Of Biochemicals In Pilot Plant Size Environment
   3/9/2010
   Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations to produce sustainable biochemicals, today announced it has successfully produced lactic acid and advanced ethanol in a commercial size facility capable of producing up to 150,000 liters of chemicals. This is an important milestone for GlycosBio and represents a major step forward as the company works towards the worldwide commercialization of its technology.
3. Exelixis Announces Restructuring
   3/8/2010
   Exelixis, Inc. today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program.
4. Research and Markets: Next Generation Biofuels: Market Drivers, Growth Opportunities and Regulatory Change
   3/4/2010
   Research and Markets (http://www.researchandmarkets.com/research/a3283f/next_generation_bi) has announced the addition of the "Next Generation Biofuels: Market Drivers, Growth Opportunities and Regulatory Change" report to their offering. Over 80% of the worlds primary energy supply is currently derived from coal, gas and oil (collectively known as fossil fuels), which are used to generate electricity, power, energy and heat for industrial, commercial, domestic and transportation purposes.
5. Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer’s Disease Clinical Development Program
   3/3/2010
   Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo.
6. Inovio Develops Cordless Electroporation Device For Delivering DNA Vaccines
   3/3/2010
   Inovio Biomedical Corporation , a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA
7. Affymetrix Launches GeneAtlas Personal Microarray System For Whole-Genome Gene Expression
   3/2/2010
   Affymetrix, Inc. today announced the launch of the GeneAtlas System, a complete, personal solution for processing Affymetrix arrays and characterizing changes in gene expression in a variety of research applications.
8. Asterand Announces The Launch Of Good Laboratory Practice (GLP) Molecular Pathology Services
   3/1/2010
   Asterand plc , a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery, recently announced that it has launched Good Laboratory Practice (GLP) compliant molecular pathology services supporting preclinical safety studies.
9. Pall Corporation Introduces Next Generation AcroPrep™ Advance Filter Plates
   2/25/2010
   Pall Corporation, a global leader in filtration, separation and purification, has introduced its next generation 96-well filter plate that delivers consistency and reproducibility in applications, such as neonatal screening and multiplexing. The Pall AcroPrep Advance filter plate employs new design features that provide uniform filtration rates, lowers hold-up volumes and ensures consistent sample/bead recovery from the wells.
10. Phase 1 Clinical Research Organization Launches New Hospital Based Unit for Clinical Trials
    2/24/2010
    Community Research, a leading US-Based Phase 1 Clinical Research Organization announced today their relocation and grand opening of their new, 15,000 sq ft clinical research facility located on the campus of Mercy Anderson Hospital, 7502 State Road, Cincinnati, OH 45255.

First 1 2 3 4 5 6 7 8 9 10 10 (Last)